<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00989469</url>
  </required_header>
  <id_info>
    <org_study_id>NEXIRI</org_study_id>
    <nct_id>NCT00989469</nct_id>
  </id_info>
  <brief_title>Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation</brief_title>
  <acronym>NEXIRI</acronym>
  <official_title>SORAFENIB (NEXAVAR®) in Combination With Irinotecan in the Second Line Treatment or More of Metastatic Colorectal Cancer With K-RAS Mutation : a Multicentre Two-part Phase I/II Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut du Cancer de Montpellier - Val d'Aurelle</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicentre two-part phase I/II study evaluating response and safety of SORAFENIB in
      combination with irinotecan in the second line treatment or more of metastatic colorectal
      cancer with K-RAS mutation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease control</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>toxicity</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Sorafenib and irinotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nexavar (Sorafenib) and irinotecan (Campto)</intervention_name>
    <description>Sorafenib administrated continuously orally 400 mg twice daily (a daily total dose of 800 mg). Irinotecan 180 mg/m² will be administered IV for 90 minutes every 2 weeks. The first dose of sorafenib will be administered after the first perfusion of irinotecan 180 mg/m² at the first infusion</description>
    <arm_group_label>Sorafenib and irinotecan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18

          -  Written informed consent

          -  Histologically proven adenocarcinoma of the colon or rectum asymptomatic primary
             tumour or surgically removed mCRC patients with previously unresectable metastatic
             disease

          -  Patient with at least one tumoral lesion: measurable in a unidimensional way with a
             spiral scanner according to RECIST, no previous irradiation in this area

          -  Disease progression after irinotecan-based chemotherapy

          -  Disease progression after one or more previous lines of chemotherapy received in
             metastatic situation

          -  WHO &lt;= 2

          -  Patient having a mutated KRAS on 12 or 13 codons on the primary tumour or a metastasis

          -  Adequate liver function : Bilirubin ≤ 1,5 x UNL, ASAT ou ALAT ≤ 2,5 x UNL (or &lt; 5 x
             UNL for subjects having a hepatic insufficiency in connection with hepatic metastases)

          -  Polynuclear neutrophils ≥ 1 500/mm3

          -  Haemoglobin &gt; 10g/dl

          -  Platelets ≥ 100 000/mm3

          -  Amylase and lipase &lt; 1,5 x UNL

          -  Serum Creatinin &lt; 1,5 x UNL

          -  Adapted contraceptive measures during treatment and continued at least three months
             after end of the treatment

          -  Life expectancy &gt; 3 months

          -  Affiliated to or benefiting from health insurance

        Exclusion Criteria:

          -  Gilbert's disease

          -  Brain metastases or carcinomatous symptomatic meningitis

          -  Exclusive bone metastasis

          -  Previous cancers not considered as cured in the 5 years before inclusion (except for
             baso-cellular skin carcinoma) Surgery (except diagnostic biopsy) or radiotherapy
             within 4 weeks before inclusion

          -  Disorders of the cardiac rhythm requiring an anti-asynchronous treatment (except beta
             blockers or digoxine within the framework of a chronic auricular fibrillation),
             unstable coronaropathy or myocardial infarction &lt; 6 months, congestive cardiac failure
             &gt; Rank II NYHA (Grade 2), uncontrolled arterial hypertension

          -  Previous epilepsy crises requiring long term antiepileptic treatment Previous organ
             transplant requiring immunosuppressor treatment Severe bacterial or fungus infection
             (&gt; Grade 2 NCI CTC version 3) Known HIV Infection

          -  Long term treatment by known inductors of the CYP 3A4 like Rifampicin, Millepertuis
             (hypericum perforatum), Phenytoin, Carbamazepin, Phenobarbital, Dexamethasone et
             Ketonazole

          -  Known allergy to one of the therapeutic agents

          -  Reasons (psychological, family, social or geographical) that could compromise the
             participation of the patient in the study

          -  Intestinal malabsorption or gastro-intestinal surgery being able to affect Sorafenib
             absorption. Occlusive or sub-occlusive syndrome.

          -  Dysphagic patient or patient not being able to take treatment by orally inflammatory

          -  Chronic digestive disease involving chronic diarrhoea (NCI N+Bethesda &gt;= 1.2g)

          -  Participation in another clinical trial within 30 days before the start of this study

          -  Other concomitant experimental drugs or other concomitant anticancer agents (except
             Irinotecan and Sorafenib)

          -  Medical or psychological state that in the opinion of the investigator will not allow
             the patient to terminate the study or to understand and sign the informed consent form

          -  Pregnancy and breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmannuelle SAMALIN-SCALZI, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CRLC Val d'Aurelle-Paul Lamarque</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Rene Gauducheau</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Robert Debre</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2009</study_first_submitted>
  <study_first_submitted_qc>October 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2009</study_first_posted>
  <last_update_submitted>February 9, 2012</last_update_submitted>
  <last_update_submitted_qc>February 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

